5α-减少酶抑制剂的累积剂量与死亡率之间的差异关联
Jinhyun Kim1,2,3, Suk-Yong Jang2,4, Eun-Cheol Park5,6,7
1Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Scientific reports
|March 31, 2025
概括
这项研究发现,5-α-减少酶抑制剂 (5-ARI) 对死亡率有复杂的影响. 较低剂量可能会增加自杀风险,而较高剂量似乎可以降低BPH和AGA患者的心血管死亡率.
科学领域:
- 药理学 药理学是指药理学的学科.
- 流行病学 流行病学
- 临床医学 临床医学
背景情况:
- 累积5α-减少酶抑制剂 (5-ARI) 剂量与患者死亡率之间的关系尚未得到充分证实.
- 5-ARIs通常用于良性前列腺增生症 (BPH) 和雄激素性脱发症 (AGA).
研究的目的:
- 调查5-ARIs绝对和时间平均累积剂量与全因和因特定死亡率之间的关联.
- 在被诊断患有BPH或AGA且已使用5 - ARI的患者中分析死亡风险.
主要方法:
- 采用了一个嵌套的病例控制研究设计.
- 病例是死亡的患者,根据年龄,性别,随访持续时间和诊断日期,与多达五个对照组匹配.
- 累计定义的每日剂量 (cDDDs) 为绝对和时间平均累计5-ARI暴露计算.
主要成果:
- 总共有3084个病例和14630个对照被纳入分析.
- 较低的累积剂量 (<365cDDD和365-730cDDD) 与较高的死亡率有关.
- 较高的累积剂量 (>5840cDDDs) 与显著降低的死亡风险有关.
- 特定原因死亡率显示,在较低的累积剂量下,自杀率增加,在较高的累积剂量下,心血管死亡率降低.
结论:
- 在累积的5-ARI使用和全因死亡率之间存在着复杂的,剂量依赖的关系.
- 使用5-ARI的患者需要仔细监测,特别是在较低剂量时可能增加自杀风险.
- 更高的累积5-ARI剂量可能与心血管死亡率的降低有关.
相关概念视频
01:11Renal Failure: Dose Adjustments
45
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
45
01:20Comparing the Survival Analysis of Two or More Groups
96
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
96
01:12Relative Risk
98
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
98
01:21Cancer Survival Analysis
311
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
311
01:12Hazard Ratio
72
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
72
01:14Time Course of Drug Effect
1.8K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
1.8K